C-RAD has signed a letter of intent regarding its GEMini technology
Press release 2009-10-28
C-RAD AB with its three fully owned subsidiaries is all active in the field of radiation therapy. C-RAD Imaging AB and IBA Dosimetry have signed a letter of intent to develop and adapt the GEMini system to be integrated in the dosimetry program sold by IBA. The intent is, based on an agreed upon specification and time schedule , to develop a transparent radiation detector, based on the C-RAD GEMini technology. For this application the C-RAD GEMini technology is offering high resolution, low attenuation and high radiation resistance. The GEMini TD detector is planned to be part of the IBA solution to verify the actual dose delivered to patients during treatment. IBA Dosimetry is the recognized world leader in radiation therapy dosimetry and has a.o. strategic cooperations with the Swedish company RaySearch Laboratories AB. The parties have the intention to sign an agreement not later than 31 December 2009. In parallel with negotiations technical performances will be evaluated by the parties. Erik Hedlund, CEO, C-RAD AB: " The IBA main requirements for a transparent radiation detector are challenging but can with the unique C-RAD GEMini technology be offered. The system will be compatible with the modern treatment technologies and contribute to an even more efficient and accurate patient treatment.” For further information: Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se ABOUT IBA Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization. Listed on the pan-European stock exchange Euronext, IBA is included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Website: http://www.iba-worldwide.com